Want to see NUWE full AI Analyst Report?
NUWE Stock Chart & Stats
$1.76
-$0.08(-7.15%)
At close: 4:00 PM EST
$1.76
-$0.08(-7.15%)
Day’s Range― - ―
52-Week Range$2.87 - $908.25
Previous CloseN/A
Volume102.02K
Average Volume (3M)289.18K
Market Cap
$1.15M
Enterprise Value-$1.69M
Total Cash (Recent Filing)$2.08M
Total Debt (Recent Filing)$265.00K
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Aug 11, 2026EPS Estimate
-23.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2240.70
Shares Outstanding364,295
10 Day Avg. Volume82,161
30 Day Avg. Volume289,177
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)4.58
Price to Sales (P/S)1.45
P/FCF Ratio-1.10
Enterprise Value/Market Cap-1.48
Enterprise Value/Revenue-0.19
Enterprise Value/Gross Profit-0.29
Enterprise Value/Ebitda0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-80.15
Revenue Forecast (FY)$9.87M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~70% gross margins indicate strong unit economics for Aquadex treatments. Higher margins from pricing, favorable mix and contract manufacturing materially improve the path to scalable profitability as installed base and procedure volume grow, reducing the revenue needed to approach breakeven.
Recurring Consumables & Installed BaseA hardware-plus-consumables model creates predictable annuity revenue: each placed console drives repeat circuit purchases. Continued console placements and a 15% increase in circuit sales suggest growing attach rates and procedure volume, supporting durable revenue per installed device over time.
Product & Clinical ExpansionAdding RendiaTech and issuing a pediatric safety patent expands the clinical platform beyond ultrafiltration, increasing clinical differentiation and potential software/monitoring revenue. Strong clinical hires and IP deepen barriers to entry and can raise customer stickiness as the platform broadens.
Bears Say
Persistent Cash BurnMulti-year negative operating and free cash flow at this scale creates ongoing financing risk. With only modest cash on the balance sheet, the company remains reliant on external funding or rapid execution of its burn‑reduction plan; failure to hit targets risks dilution or constrained operations.
Small Revenue Scale Vs. LossesDespite strong percentage growth, absolute revenue is small relative to fixed costs and operating spend. Large recurring operating losses mean the company must materially scale sales or cut costs to approach profitability; the current scale gap presents a durable execution risk over the next several quarters.
Governance & Board InstabilityDirector resignations and a public governance dispute raise oversight and continuity concerns. Persistent internal disagreement can distract management, complicate strategic decisions, hamper fundraising or partner confidence, and slow implementation of the commercial and cost initiatives needed to stabilize the business.
Nuwellis News
NUWE FAQ
What was Nuwellis’s price range in the past 12 months?
Nuwellis lowest stock price was $2.87 and its highest was $908.25 in the past 12 months.
What is Nuwellis’s market cap?
Nuwellis’s market cap is $1.15M.
When is Nuwellis’s upcoming earnings report date?
Nuwellis’s upcoming earnings report date is Aug 11, 2026 which is in 38 days.
How were Nuwellis’s earnings last quarter?
Nuwellis released its earnings results on May 12, 2026. The company reported -$73.15 earnings per share for the quarter, missing the consensus estimate of -$35 by -$38.15.
Is Nuwellis overvalued?
According to Wall Street analysts Nuwellis’s price is currently Overvalued.
Does Nuwellis pay dividends?
Nuwellis does not currently pay dividends.
What is Nuwellis’s EPS estimate?
Nuwellis’s EPS estimate is -23.8.
How many shares outstanding does Nuwellis have?
Nuwellis has 364,295 shares outstanding.
What happened to Nuwellis’s price movement after its last earnings report?
Nuwellis reported an EPS of -$73.15 in its last earnings report, missing expectations of -$35. Following the earnings report the stock price went down -0.959%.
Which hedge fund is a major shareholder of Nuwellis?
Currently, no hedge funds are holding shares in NUWE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
NUWE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple positive operational and strategic developments (notably 26% revenue growth, a 70.1% gross margin, pediatric adoption, the RendiaTech acquisition, a new patent, leadership and board strengthening, and a ~$5M capital infusion). However, notable challenges remain: a ~$4.3M net loss, operating expenses up ~46%, modest cash on hand (~$2.2M), and a multi-quarter timeline to commercialize RendiaTech's target product. On balance, the highlights indicate meaningful early execution progress and strategic positioning, but the company must deliver on its burn reduction and commercialization milestones to sustain momentum.View all NUWE earnings summariesNUWE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aethlon Medical
―
PAVmed
―
Catheter Precision
―
Bone Biologics
―
Heart Test Laboratories, Inc.
―
Ownership Overview
<0.01% Insiders
3.69% Mutual Funds
― Other Institutional Investors
96.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---